Three-year update of sildenafil citrate (Viagra®) efficacy and safety

R. Sadovsky*, T. Miller, M. Moskowitz, G. Hackett

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

130 Scopus citations

Abstract

In the three years since its launch, sildenafil citrate (Viagra®), an oral agent for the treatment of erectile dysfunction (ED), has been prescribed to more than 10 million patients worldwide and has been further evaluated in clinical studies in diverse patient populations. Significant improvements in erectile function have been demonstrated in double-blind, placebo-controlled trials in patients with ED and underlying diabetes, cardiovascular disease, minor depression, spinal cord injury and multiple sclerosis. Promising results have also been reported for patients with treated prostate cancer, end-stage renal failure, Parkinson's disease, and spina bifida and in multiple organ transplant recipients. Accounts of sildenafil use in clinical practice and postmarketing data reflect clinical trial findings of effectiveness in a broad spectrum of ED aetiologies and overall good tolerability. As in the clinical trials, most adverse events associated with sildenafil use have been transient, mild or moderate effects that rarely lead to treatment discontinuation.

Original languageEnglish
Pages (from-to)115-128
Number of pages14
JournalInternational Journal of Clinical Practice
Volume55
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Dive into the research topics of 'Three-year update of sildenafil citrate (Viagra®) efficacy and safety'. Together they form a unique fingerprint.

Cite this